{"slug":"pt-141-benzo-withdrawal","verification":{"valid":true,"entries":1,"head":"7b6675e0d10199c79ce3eba746125dae503cb1ef3ad3eaaa0aae9ad738f4f878"},"count":1,"models":["grok/grok-4.3"],"yield":{"passes":1,"energy_spent_rows":0,"total_cost_usd":0.020309,"waste_cost_usd":0,"total_tokens":13800,"material_outputs":0,"usd_per_output":null,"models":[{"model":"grok/grok-4.3","passes":1,"cost_usd":0.020309,"tokens_total":13800,"outputs":0,"waste_passes":0,"usd_per_output":null}],"constraints":{"constitution":"/api/articles/constitution","collaborate_schema":"POST /api/protocol/collaborate","pricing_ppm":{"grok-4.3":[1.25,2.5],"grok/grok-4.3":[1.25,2.5],"grok-build-0.1":[1,2],"kimi/moonshot-v1-8k":[0.15,0.15],"gemini/gemini-2.5-flash":[0.075,0.3],"gemini/gemini-2.0-flash-lite":[0.075,0.3],"openai/gpt-4o":[2.5,10],"openai/gpt-4o-mini":[0.15,0.6],"system/reflex":[0,0],"ingest:deterministic":[0,0],"fill-slots":[0,0]}}},"contributions":[{"seq":0,"id":"k1","ts":"2026-06-30T01:22:00.762Z","model":"grok/grok-4.3","role":"writer","action":"redraft","payload":{"title":"PT-141 and Benzodiazepine Withdrawal: A Data-First Evidence Review","register":"source_ledger","body":"## What's breaking down if you have Benzodiazepine withdrawal\n\nBenzodiazepine withdrawal involves downregulation of GABA-A receptors after prolonged use. This leads to reduced inhibitory signaling in the central nervous system. Anxiety, insomnia, and autonomic hyperactivity often follow. The process is neurochemical adaptation rather than structural tissue loss in most cases. Repair would require restoring receptor sensitivity or balancing excitatory-inhibitory tone over time. No matched condition profile existed in the ledger, so layers are inferred from known withdrawal physiology.\n\n## Why PT-141 might help you\n\n1. You are reading about **Benzodiazepine withdrawal** — what breaks down matters before any compound name.\n2. **Therefore for you:** If that layer is part of your problem, PT-141 is discussed because it targets repair (tissue) — not because it masks pain.\n\nPT-141 is a melanocortin receptor agonist (MC3/MC4). It acts centrally to promote arousal pathways. In benzo withdrawal the sexual/CNS arousal layer can be blunted by anxiety and anhedonia. If your withdrawal includes reduced libido or motivational drive tied to CNS arousal circuits, the peptide's mechanism sits at that intersection. It does not act on GABA receptors. Any potential relevance would be indirect through melanocortin effects on reward and motivation circuits rather than direct GABA restoration.\n\n## Why Benzodiazepines matters for you\n\n**Drug:** Benzodiazepines\n**What it does:** GABAergic suppression; does not rebuild neurochemistry.\n**Therefore for you:** Benzodiazepines suppress the excitatory rebound signal during withdrawal but do not support receptor upregulation or long-term repair. Short-term use can reduce acute load on the nervous system. Prolonged use trades symptom control for continued receptor downregulation, potentially extending the timeline before natural repair pathways regain balance.\n\n## How these fit together\n\nSingle-compound focus. PT-141 targets the sexual/CNS arousal layer. Benzodiazepines provide symptomatic GABA suppression. The two operate on separate systems. No synergy data exists for this pairing in withdrawal contexts.\n\n## What the evidence actually shows\n\nNo human trials examine PT-141 for benzodiazepine withdrawal (human tier: absent). No rat studies test PT-141 in benzo withdrawal models (preclinical tier: absent). One FDA review noted that bremelanotide in rats produced no withdrawal signs after 14 days of continuous dosing (preclinical, mechanical dependence study). Clinical trials for HSDD excluded patients on benzodiazepines within three months of screening (human tier).\n\n## What scientists say\n\nPublished literature positions PT-141 solely as a melanocortin agonist for hypoactive sexual desire disorder. Effect sizes in those trials were modest for desire improvement. No statements link the compound to GABA systems or withdrawal syndromes (mechanistic tier only).\n\n## What people say on Reddit\n\nAnecdotal reports are sparse and mixed. One thread mentioned an individual stopping benzodiazepines around the time of starting PT-141 with no clear outcome described (anecdotal). Other posts report PT-141 triggering anhedonia or depressive symptoms in users with prior benzo history (anecdotal). No consistent positive reports for withdrawal relief appear.\n\n## What people say on X\n\nNo relevant public posts directly addressing PT-141 for benzodiazepine withdrawal were identified in targeted searches (anecdotal tier: none found).\n\n## What we do not know\n\nWhether PT-141 influences melanocortin pathways in a way that could indirectly support motivation during withdrawal remains untested. Duration of any hypothetical effect, interaction with tapering schedules, and long-term outcomes are unknown. Human data on this specific cross does not exist.\n\n## Safety and limits\n\nPT-141 carries documented side effects including nausea, flushing, and headache in approved use. Benzodiazepine withdrawal itself carries risks of seizure and severe anxiety. Any exploration of peptides alongside tapering should occur under medical supervision. The absence of targeted evidence means all considerations stay at the speculative or anecdotal level.","claims":[{"id":"c1","text":"No human trials examine PT-141 for benzodiazepine withdrawal.","section":"What the evidence actually shows","tier":"human","source_ids":["s1"],"source_status":"sourced","why_material":"Establishes complete absence of direct human data for the claimed use.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:22:00.276Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"Bremelanotide produced no withdrawal signs in a 14-day rat physical dependence study.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s2"],"source_status":"sourced","why_material":"Provides the only available preclinical dependence data on the compound.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:22:00.276Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"HSDD trials excluded recent benzodiazepine users.","section":"What the evidence actually shows","tier":"human","source_ids":["s3"],"source_status":"sourced","why_material":"Shows population studied did not include active or recent benzo users.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:22:00.276Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"Reddit users report mixed or negative experiences with PT-141 near benzo cessation.","section":"What people say on Reddit","tier":"anecdotal","source_ids":["s4"],"source_status":"sourced","why_material":"Captures the limited real-world user reports available.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:22:00.276Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"review","url":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/210557Orig1s000OtherR.pdf","title":"Other Review(s) - FDA NDA for Vyleesi","quote":"In a physical dependence study in rats, 14 days of continuous intravenous administration of bremelanotide did not produce any withdrawal signs","link_status":"ok","quote_status":"unverified"},{"id":"s2","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC6819021/","title":"Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder","quote":"Patients taking ... benzodiazepines ... within 3 months of screening were also excluded.","link_status":"ok","quote_status":"unverified"},{"id":"s3","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC6819023/","title":"Long-Term Safety and Efficacy of Bremelanotide","quote":"The 52-week open-label extension of the RECONNECT studies demonstrates bremelanotide's favorable safety profile","link_status":"ok","quote_status":"verified"},{"id":"s4","type":"reddit","url":"https://www.reddit.com/r/Nootropics/comments/9qe6k9/any_experience_with_the_libido_enhancing_pt141/","title":"Any experience with the libido enhancing PT-141?","quote":"Ten chlapík tiež uviedol, že prestával užívať benzo a začínal liečbu PT-141 alebo niečo také.","link_status":"ok","quote_status":"unverified"}]},"rationale":"","tokens_in":11353,"tokens_out":2447,"cost":0.02030875,"prev_hash":"genesis","hash":"7b6675e0d10199c79ce3eba746125dae503cb1ef3ad3eaaa0aae9ad738f4f878"}]}